Comparative study of lacidipine and nicidipine SR in the treatment of hypertension: An italian multicenter study

Gastone Leonetti, E. Ambrosioni, D. Bracchetti, F. Barbaresi, A. Baronchelli, D. Basevi, L. Bertoni, G. De Sandre, L. Scuro, G. Bazzato, A. Bossini, V. Cagli, L. Corea, C. Dal Palu, G. Falezza, R. Fogari, G. Galvanini, O. Ghidini, F. Giungi, A. LibrettiA. Zanchetti, C. Mazzola, C. Pasotti, I. Portioli, E. Pretolani, A. Rappelli, M. Timio, G. Tumiotto, E. Zerbini

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The aim of this study was to compare the antihypertensive efficacy and tolerability of lacidipine, a new dihydropyridine calcium antagonist, and slow-release nifedipine (SR) in patients with mild-to-moderate essential hypertension. After a 1-month placebo run-in period, 435 patients were randomized into a double-blind, parallel-group study to receive either 4 mg of lacidipine once daily (n = 220) or 20 mg of nifedipine twice daily (n = 215). After4 weeks, the doses for "nonresponders" were increased to 6 mg of lacidipine once daily (n= 82) and to 40 mg of nifedipine SR twice daily (n = 62). After 4 weeks, 50 mg of atenolol once daily was added to the regimens of patients still uncontrolled by lacidipine (n =32) and nifedipine SR (n = 23) as monotherapy. Sitting blood pressure and heart rate were measured at 22-24 h after lacidipine and 10-12 h after nifedipine SR. Both calcium antagonists similarly and significantly reduced the blood pressure at rest (sitting) and on exercise, while the heart rate did not change significantly. The nature and incidence of side effects and withdrawals also did not differ between the two. In conclusion, lacidipine once daily is as effective and well tolerated as nifedipine SR twice daily in patients with mild-to-moderate essential hypertension.

Original languageEnglish
Pages (from-to)S31-S34
JournalJournal of Cardiovascular Pharmacology
Volume17
Publication statusPublished - 1991

Fingerprint

Nifedipine
Multicenter Studies
Hypertension
Therapeutics
Heart Rate
lacidipine
Blood Pressure
Calcium
Atenolol
Antihypertensive Agents
Placebos
Exercise
Incidence

Keywords

  • Antihypertensive treatment
  • Calcium antagonists
  • Exercise endurance
  • Lacidipine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Leonetti, G., Ambrosioni, E., Bracchetti, D., Barbaresi, F., Baronchelli, A., Basevi, D., ... Zerbini, E. (1991). Comparative study of lacidipine and nicidipine SR in the treatment of hypertension: An italian multicenter study. Journal of Cardiovascular Pharmacology, 17, S31-S34.

Comparative study of lacidipine and nicidipine SR in the treatment of hypertension : An italian multicenter study. / Leonetti, Gastone; Ambrosioni, E.; Bracchetti, D.; Barbaresi, F.; Baronchelli, A.; Basevi, D.; Bertoni, L.; De Sandre, G.; Scuro, L.; Bazzato, G.; Bossini, A.; Cagli, V.; Corea, L.; Dal Palu, C.; Falezza, G.; Fogari, R.; Galvanini, G.; Ghidini, O.; Giungi, F.; Libretti, A.; Zanchetti, A.; Mazzola, C.; Pasotti, C.; Portioli, I.; Pretolani, E.; Rappelli, A.; Timio, M.; Tumiotto, G.; Zerbini, E.

In: Journal of Cardiovascular Pharmacology, Vol. 17, 1991, p. S31-S34.

Research output: Contribution to journalArticle

Leonetti, G, Ambrosioni, E, Bracchetti, D, Barbaresi, F, Baronchelli, A, Basevi, D, Bertoni, L, De Sandre, G, Scuro, L, Bazzato, G, Bossini, A, Cagli, V, Corea, L, Dal Palu, C, Falezza, G, Fogari, R, Galvanini, G, Ghidini, O, Giungi, F, Libretti, A, Zanchetti, A, Mazzola, C, Pasotti, C, Portioli, I, Pretolani, E, Rappelli, A, Timio, M, Tumiotto, G & Zerbini, E 1991, 'Comparative study of lacidipine and nicidipine SR in the treatment of hypertension: An italian multicenter study', Journal of Cardiovascular Pharmacology, vol. 17, pp. S31-S34.
Leonetti G, Ambrosioni E, Bracchetti D, Barbaresi F, Baronchelli A, Basevi D et al. Comparative study of lacidipine and nicidipine SR in the treatment of hypertension: An italian multicenter study. Journal of Cardiovascular Pharmacology. 1991;17:S31-S34.
Leonetti, Gastone ; Ambrosioni, E. ; Bracchetti, D. ; Barbaresi, F. ; Baronchelli, A. ; Basevi, D. ; Bertoni, L. ; De Sandre, G. ; Scuro, L. ; Bazzato, G. ; Bossini, A. ; Cagli, V. ; Corea, L. ; Dal Palu, C. ; Falezza, G. ; Fogari, R. ; Galvanini, G. ; Ghidini, O. ; Giungi, F. ; Libretti, A. ; Zanchetti, A. ; Mazzola, C. ; Pasotti, C. ; Portioli, I. ; Pretolani, E. ; Rappelli, A. ; Timio, M. ; Tumiotto, G. ; Zerbini, E. / Comparative study of lacidipine and nicidipine SR in the treatment of hypertension : An italian multicenter study. In: Journal of Cardiovascular Pharmacology. 1991 ; Vol. 17. pp. S31-S34.
@article{93b5b07a212840e4877db3ee7eaf5d49,
title = "Comparative study of lacidipine and nicidipine SR in the treatment of hypertension: An italian multicenter study",
abstract = "The aim of this study was to compare the antihypertensive efficacy and tolerability of lacidipine, a new dihydropyridine calcium antagonist, and slow-release nifedipine (SR) in patients with mild-to-moderate essential hypertension. After a 1-month placebo run-in period, 435 patients were randomized into a double-blind, parallel-group study to receive either 4 mg of lacidipine once daily (n = 220) or 20 mg of nifedipine twice daily (n = 215). After4 weeks, the doses for {"}nonresponders{"} were increased to 6 mg of lacidipine once daily (n= 82) and to 40 mg of nifedipine SR twice daily (n = 62). After 4 weeks, 50 mg of atenolol once daily was added to the regimens of patients still uncontrolled by lacidipine (n =32) and nifedipine SR (n = 23) as monotherapy. Sitting blood pressure and heart rate were measured at 22-24 h after lacidipine and 10-12 h after nifedipine SR. Both calcium antagonists similarly and significantly reduced the blood pressure at rest (sitting) and on exercise, while the heart rate did not change significantly. The nature and incidence of side effects and withdrawals also did not differ between the two. In conclusion, lacidipine once daily is as effective and well tolerated as nifedipine SR twice daily in patients with mild-to-moderate essential hypertension.",
keywords = "Antihypertensive treatment, Calcium antagonists, Exercise endurance, Lacidipine",
author = "Gastone Leonetti and E. Ambrosioni and D. Bracchetti and F. Barbaresi and A. Baronchelli and D. Basevi and L. Bertoni and {De Sandre}, G. and L. Scuro and G. Bazzato and A. Bossini and V. Cagli and L. Corea and {Dal Palu}, C. and G. Falezza and R. Fogari and G. Galvanini and O. Ghidini and F. Giungi and A. Libretti and A. Zanchetti and C. Mazzola and C. Pasotti and I. Portioli and E. Pretolani and A. Rappelli and M. Timio and G. Tumiotto and E. Zerbini",
year = "1991",
language = "English",
volume = "17",
pages = "S31--S34",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Comparative study of lacidipine and nicidipine SR in the treatment of hypertension

T2 - An italian multicenter study

AU - Leonetti, Gastone

AU - Ambrosioni, E.

AU - Bracchetti, D.

AU - Barbaresi, F.

AU - Baronchelli, A.

AU - Basevi, D.

AU - Bertoni, L.

AU - De Sandre, G.

AU - Scuro, L.

AU - Bazzato, G.

AU - Bossini, A.

AU - Cagli, V.

AU - Corea, L.

AU - Dal Palu, C.

AU - Falezza, G.

AU - Fogari, R.

AU - Galvanini, G.

AU - Ghidini, O.

AU - Giungi, F.

AU - Libretti, A.

AU - Zanchetti, A.

AU - Mazzola, C.

AU - Pasotti, C.

AU - Portioli, I.

AU - Pretolani, E.

AU - Rappelli, A.

AU - Timio, M.

AU - Tumiotto, G.

AU - Zerbini, E.

PY - 1991

Y1 - 1991

N2 - The aim of this study was to compare the antihypertensive efficacy and tolerability of lacidipine, a new dihydropyridine calcium antagonist, and slow-release nifedipine (SR) in patients with mild-to-moderate essential hypertension. After a 1-month placebo run-in period, 435 patients were randomized into a double-blind, parallel-group study to receive either 4 mg of lacidipine once daily (n = 220) or 20 mg of nifedipine twice daily (n = 215). After4 weeks, the doses for "nonresponders" were increased to 6 mg of lacidipine once daily (n= 82) and to 40 mg of nifedipine SR twice daily (n = 62). After 4 weeks, 50 mg of atenolol once daily was added to the regimens of patients still uncontrolled by lacidipine (n =32) and nifedipine SR (n = 23) as monotherapy. Sitting blood pressure and heart rate were measured at 22-24 h after lacidipine and 10-12 h after nifedipine SR. Both calcium antagonists similarly and significantly reduced the blood pressure at rest (sitting) and on exercise, while the heart rate did not change significantly. The nature and incidence of side effects and withdrawals also did not differ between the two. In conclusion, lacidipine once daily is as effective and well tolerated as nifedipine SR twice daily in patients with mild-to-moderate essential hypertension.

AB - The aim of this study was to compare the antihypertensive efficacy and tolerability of lacidipine, a new dihydropyridine calcium antagonist, and slow-release nifedipine (SR) in patients with mild-to-moderate essential hypertension. After a 1-month placebo run-in period, 435 patients were randomized into a double-blind, parallel-group study to receive either 4 mg of lacidipine once daily (n = 220) or 20 mg of nifedipine twice daily (n = 215). After4 weeks, the doses for "nonresponders" were increased to 6 mg of lacidipine once daily (n= 82) and to 40 mg of nifedipine SR twice daily (n = 62). After 4 weeks, 50 mg of atenolol once daily was added to the regimens of patients still uncontrolled by lacidipine (n =32) and nifedipine SR (n = 23) as monotherapy. Sitting blood pressure and heart rate were measured at 22-24 h after lacidipine and 10-12 h after nifedipine SR. Both calcium antagonists similarly and significantly reduced the blood pressure at rest (sitting) and on exercise, while the heart rate did not change significantly. The nature and incidence of side effects and withdrawals also did not differ between the two. In conclusion, lacidipine once daily is as effective and well tolerated as nifedipine SR twice daily in patients with mild-to-moderate essential hypertension.

KW - Antihypertensive treatment

KW - Calcium antagonists

KW - Exercise endurance

KW - Lacidipine

UR - http://www.scopus.com/inward/record.url?scp=0025870360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025870360&partnerID=8YFLogxK

M3 - Article

C2 - 1726003

AN - SCOPUS:0025870360

VL - 17

SP - S31-S34

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

ER -